Home LiteratureArticle Details
PMID: 22778805 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Engineering a GPCR-ligand pair that simulates the activation of D(2L) by Dopamine.

ACS chemical neuroscience ·Vol. 1 ·No. 1 ·2010-01-20 ·Pages 25-35

Tschammer N, Dörfler M, Hübner H, Gmeiner P

Abstract

In the past decade, engineered G-protein-coupled receptors activated solely by synthetic ligands (RASSLs) have been implemented as a new means to study neurotransmission, which is controlled by G-protein-coupled receptors in vitro and in vivo. In this study, we report an engineered dopamine receptor D(2L) F390(6.52)W, which is the first identified RASSL for the dopamine receptor family. The mutant receptor is characterized by a disrupted ligand binding and complete loss of efficacy for the endogenous ligand, dopamine, which is putatively due to a sterically induced perturbation of H-bonding with conserved serine residues in TM5. Based on this model, we rationally developed an aminoindane-derived set of agonists. Because these agonists forgo analogous H-bonding functionalities, their binding energy does not depend on the respective interactions. Binding affinity and potency were optimized by ligand modifications bearing molecular appendages that obviously interact with a secondary recognition site provided by four hydrophobic residues in TM2 and TM3. Thus, the ferrocenyl carboxamide 5b (FAUC 185) was identified as a synthetic agonist that is able to stimulate the mutant receptor in a manner similar to that by which endogenous dopamine activates the D(2L) wild-type receptor. The engineered dopamine receptor D(2L) F390(6.52)W in combination with FAUC 185 (5b) provides a new tool to probe GPCR functions selectively in specific cell populations in vitro and in vivo.

Keywords
Dopamine D2L receptor G-protein-coupled receptor GPCR aminoindane engineered receptor ferrocenyl carboxamide receptor activated solely by synthetic ligands RASSL
MeSH Terms
Animals CHO Cells Cell Membrane/chemistry,metabolism Cloning, Molecular Cricetinae Cricetulus Cyclic AMP/biosynthesis Drug Design Enzyme-Linked Immunosorbent Assay Guanosine 5'-O-(3-Thiotriphosphate)/analysis,metabolism Humans Indicators and Reagents Ligands MAP Kinase Signaling System/drug effects Models, Molecular Mutagenesis, Site-Directed Mutation Receptors, Dopamine D2/chemistry,genetics Receptors, G-Protein-Coupled/agonists,chemistry,genetics Structure-Activity Relationship
Chemicals
Indicators and Reagents Ligands Receptors, Dopamine D2 Receptors, G-Protein-Coupled dopamine D2L receptor Guanosine 5'-O-(3-Thiotriphosphate) Cyclic AMP
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Tschammer Nuska
Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich Alexander University, Schuhstrasse 19, D-91052 Erlangen, Germany.
Dörfler Miriam
Hübner Harald
Gmeiner Peter
References (52)
52 references, click to expand
  1. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction.
    J Neurochem. 1995 Nov;65(5):2105-15 PMID: 7595496
  2. Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.
    Br J Pharmacol. 2000 Aug;130(7):1505-12 PMID: 10928951
  3. Three-dimensional representations of G protein-coupled receptor structures and mechanisms.
    Methods Enzymol. 2002;343:329-71 PMID: 11665578
  4. Catecholamines-crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening pandora's box?
    Mol Med. 2008 Mar-Apr;14(3-4):195-204 PMID: 18079995
  5. Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles.
    J Med Chem. 2005 Jun 2;48(11):3696-9 PMID: 15916420
  6. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
    Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 PMID: 4202581
  7. Suggestions for "safe" residue substitutions in site-directed mutagenesis.
    J Mol Biol. 1991 Feb 20;217(4):721-9 PMID: 2005621
  8. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.
    J Med Chem. 2005 Feb 10;48(3):694-709 PMID: 15689154
  9. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
    Neuropharmacology. 2009 May-Jun;56(6-7):956-69 PMID: 19371586
  10. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype.
    J Med Chem. 2000 Feb 24;43(4):756-62 PMID: 10691700
  11. A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL).
    J Biol Chem. 2003 Jan 10;278(2):699-702 PMID: 12441358
  12. Effect of multiple serine/alanine mutations in the transmembrane spanning region V of the D2 dopamine receptor on ligand binding.
    J Neurochem. 2000 Jan;74(1):358-66 PMID: 10617140
  13. The receptors and coding logic for bitter taste.
    Nature. 2005 Mar 10;434(7030):225-9 PMID: 15759003
  14. New tools to build synthetic hormonal pathways.
    Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4777-8 PMID: 17360323
  15. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.
    Chem Rev. 2007 Jan;107(1):274-302 PMID: 17212477
  16. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations.
    Mol Pharmacol. 1998 Aug;54(2):435-44 PMID: 9687586
  17. Subtype selective tetracycline agonists and their application for a two-stage regulatory system.
    Chembiochem. 2006 Sep;7(9):1320-4 PMID: 16871602
  18. Engineered GPCRs as tools to modulate signal transduction.
    Physiology (Bethesda). 2008 Dec;23:313-21 PMID: 19074739
  19. Fancy bioisosteres: novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists.
    J Med Chem. 2006 Jun 15;49(12):3628-35 PMID: 16759104
  20. Controlling signaling with a specifically designed Gi-coupled receptor.
    Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):352-7 PMID: 9419379
  21. A G(q/11)-coupled mutant histamine H(1) receptor F435A activated solely by synthetic ligands (RASSL).
    J Biol Chem. 2005 Oct 14;280(41):34741-6 PMID: 16027157
  22. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.
    Science. 2008 Nov 21;322(5905):1211-7 PMID: 18832607
  23. The neurobiology of dopamine signaling.
    Arch Neurol. 2004 May;61(5):641-4 PMID: 15148138
  24. Engineering receptors activated solely by synthetic ligands (RASSLs).
    Trends Pharmacol Sci. 2001 Aug;22(8):414-20 PMID: 11479004
  25. Allele-specific activation of genetically engineered receptors.
    J Biol Chem. 1991 Jan 5;266(1):5-8 PMID: 1670767
  26. G-protein-coupled receptors at a glance.
    J Cell Sci. 2003 Dec 15;116(Pt 24):4867-9 PMID: 14625380
  27. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism.
    Neuroimmunomodulation. 2001;9(1):23-33 PMID: 11435749
  28. Unravelling multiple ligand-activation binding sites using RASSL receptors.
    Trends Pharmacol Sci. 2003 Oct;24(10):504-7 PMID: 14559400
  29. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.
    J Med Chem. 2009 Aug 13;52(15):4923-35 PMID: 19606869
  30. Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene.
    J Med Chem. 1980 Jul;23(7):745-9 PMID: 7190613
  31. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.
    Science. 2007 Nov 23;318(5854):1258-65 PMID: 17962520
  32. Brain dopamine and obesity.
    Lancet. 2001 Feb 3;357(9253):354-7 PMID: 11210998
  33. The estrogen receptor: a structure-based approach to the design of new specific hormone-receptor combinations.
    Chem Biol. 2001 Mar;8(3):277-87 PMID: 11306352
  34. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function.
    Science. 2007 Nov 23;318(5854):1266-73 PMID: 17962519
  35. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration.
    J Neurosci. 2004 Jul 7;24(27):6133-43 PMID: 15240805
  36. Parallel synthesis and biological screening of dopamine receptor ligands taking advantage of a click chemistry based BAL linker.
    J Comb Chem. 2005 Mar-Apr;7(2):309-16 PMID: 15762761
  37. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
    J Med Chem. 2005 Sep 8;48(18):5771-9 PMID: 16134944
  38. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand.
    Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5163-8 PMID: 17360345
  39. Molecular mechanism of 7TM receptor activation--a global toggle switch model.
    Annu Rev Pharmacol Toxicol. 2006;46:481-519 PMID: 16402913
  40. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice.
    Biochemistry. 1998 Jan 27;37(4):998-1006 PMID: 9454590
  41. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin.
    Biochemistry. 2003 Mar 18;42(10):2759-67 PMID: 12627940
  42. Engineering orthogonal ligand-receptor pairs from "near drugs".
    J Am Chem Soc. 2001 Nov 21;123(46):11367-71 PMID: 11707111
  43. Molecular evolution of adrenoceptors and dopamine receptors: implications for the binding of catecholamines.
    J Med Chem. 2006 Mar 9;49(5):1706-19 PMID: 16509586
  44. Structure of a beta1-adrenergic G-protein-coupled receptor.
    Nature. 2008 Jul 24;454(7203):486-91 PMID: 18594507
  45. Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.
    J Med Chem. 2001 Nov 22;44(24):4125-36 PMID: 11708915
  46. Engineering the melanocortin-4 receptor to control G(s) signaling in vivo.
    Ann N Y Acad Sci. 2003 Jun;994:225-32 PMID: 12851320
  47. A gene regulation system with four distinct expression levels.
    J Gene Med. 2006 Aug;8(8):1037-47 PMID: 16779863
  48. Structure-based design of Tet repressor to optimize a new inducer specificity.
    Biochemistry. 2004 Jul 27;43(29):9512-8 PMID: 15260494
  49. Engineering GPCR signaling pathways with RASSLs.
    Nat Methods. 2008 Aug;5(8):673-8 PMID: 18668035
  50. Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies.
    J Med Chem. 2008 Nov 13;51(21):6829-38 PMID: 18834111
  51. Dopamine receptor microdomains involved in molecular recognition and the regulation of drug affinity and function.
    J Recept Signal Transduct Res. 2004 Aug;24(3):207-39 PMID: 15521362
  52. Protein measurement with the Folin phenol reagent.
    J Biol Chem. 1951 Nov;193(1):265-75 PMID: 14907713
Article Info
Journal
ACS chemical neuroscience
Abbr.
ACS Chem Neurosci
ISSN
1948-7193
Published
2010-01-20
Epub
2009-00-24
Pages
25-35
Language
English
Region
United States
NLM ID
101525337
PMCID
PMC3368624
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com